Why did Align Technology (ALGN) stock move recently?

On 9/1/2026, Align Technology moved -3.0% — ALGN fell 3% with no company-specific news or filing today; the move appears to reflect broader market or sector trading after recent board refreshment and China patent updates. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Align Technology (ALGN) overvalued or fairly valued?

MarketChacha shows Align Technology's valuation in context — a trailing P/E of about 26.9, a forward P/E of about 12.1, a price-to-book of about 2.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Align Technology's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.66×) from reported figures — education, not a rating.

What is Align Technology's revenue?

Align Technology reported revenue of $4.0B for FY2025, with net profit of $410.4M, per official filings.

What is the share price of Align Technology (ALGN)?

Align Technology last traded at $150.00 (+0.7% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Align Technology

ALGN · NYSE · Healthcare · United States

Snapshot

TickerALGN

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees20,435

HeadquartersTempe, United States

Websitewww.aligntech.com

Filings tracked19

About Align Technology

Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth. This segment also provides Invisalign express, Invisalign lite, and Invisalign moderate; Invisalign Go, Invisalign Go express, and Invisalign Go Plus; retention products, Invisalign training, adjusting tools used by dental professionals during treatment, ancillary Invisalign accessory products, and other oral health products; Invisalign Professional Whitening system; Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; exocad, a computer-aided design and computer-aided manufacturing software; orthodontist software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers; and restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons. This segment also offers Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface for dental consultations; iTero TimeLapse technology for doctors or practitioners to compare a patient's historic 3D scans to the present-day scan; and subscription software, disposables, rents scanners, and pay per scan services. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Who owns it

Insiders6.1%
Institutions93.9%
Public & other0.0%

960 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.6.17%
Vanguard Capital Management LLC6.15%
FMR, LLC5.67%
Capital International Investors5.65%
Capital World Investors4.78%
Goldman Sachs Group Inc4.71%
Vanguard Portfolio Management LLC4.37%
State Street Corporation3.57%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.66×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend11.5% → 10.2%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 2% · PAT -4%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.1B · EPS 3.19

Est. earnings growth -3.0%

Next fiscal year

Rev $4.3B · EPS 12.43

Est. earnings growth +10.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$4.0B

Net margin

10.2%

ROE

10.1%

Revenue CAGR (2y)

+2.2%

Profit CAGR (2y)

-4.0%

EPS (FY2025)

5.65

Net profit (FY2025)

$410.4M

Ask MarketChacha about ALGN

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Sep 1, 2026
ALGN fell 3% with no company-specific news or filing today; the move appears to reflect broader market or sector trading after recent board refreshment and China patent updates.
· confidence: low
Jul 28, 2026
ALGN rose on positive coverage of its new AI-powered workflow suite and related bull case discussion, with no major earnings release or filing today.
source 1 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$4.0B	$410.4M	5.65	10.2%	10.1%
FY2024	$4.0B	$421.4M	5.62	10.5%	10.9%
FY2023	$3.9B	$445.1M	5.81	11.5%	12.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$1.1B	$108.3M	1.51	10.3%
2026Q1	$1.0B	$112.8M	1.57	10.8%
2025Q3	$995.7M	$56.8M	0.78	5.7%
2025Q2	$1.0B	$124.6M	1.72	12.3%
2025Q1	$979.3M	$93.2M	1.27	9.5%
2024Q3	$977.9M	$116.0M	1.55	11.9%
2024Q2	$1.0B	$96.6M	1.28	9.4%
2024Q1	$997.4M	$105.0M	1.39	10.5%
2023Q3	$960.2M	$121.4M	1.58	12.6%
2023Q2	$1.0B	$111.8M	1.46	11.2%
2023Q1	$943.1M	$87.8M	1.14	9.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Exhibits
SEC8/31/2026material
10-Q filing
SEC8/5/2026
8-K — Results of operations, Exhibits
SEC7/29/2026material
8-K — Reg FD disclosure, Exhibits
SEC7/29/2026material
8-K — Executive/director change
SEC7/9/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/22/2026material
8-K — Shareholder vote results, Exhibits
SEC5/20/2026material
10-Q filing
SEC5/6/2026
8-K — Reg FD disclosure, Exhibits
SEC5/1/2026material
8-K — Results of operations, Exhibits
SEC4/29/2026material
10-K filing
SEC2/27/2026
8-K — Bylaw/charter change, Exhibits
SEC2/26/2026material
8-K — Results of operations, Exhibits
SEC2/4/2026material

2025

10-Q filing
SEC11/5/2025
8-K — Results of operations, Exhibits
SEC10/29/2025material
8-K — Executive/director change
SEC9/18/2025material
10-Q filing
SEC8/6/2025
8-K — Reg FD disclosure, Exhibits
SEC8/5/2025material
8-K — Results of operations, Exhibits
SEC7/30/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.